The Food and Drug Administration (FDA) has drawn attention to efficacy issues associated with Keytruda or Tecentriq in some clinical trials - patients and healthcare professionals should take note.

The trials identified are those in which Keytruda (pembrolizumab) or Tecentriq (atezolizumab) is used as single therapy for metastatic urothelial (bladder) cancer patients who have not received prior therapy, and who have low expression of the protein programmed death ligand 1 (PD-L1), which is the path targeted by the drug.

Read more on the FDA website.